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Abstract
Multiple myeloma (MM) is one of the commonest hematological malignancies of public
health importance especially in low-income countries (LICs) of Sub-Saharan Africa.
The two major challenges in the management of MM in developing countries are in the
diagnosis and treatment. It poses diagnostic dilemma to physicians, especially orthopedic
surgeons, because of the skeletal related events (SREs). Lack of modern equipment for
diagnosis is a key player in late diagnosis of MM, and the management follows a pallia-
tive approach in the region. There is a gross inadequacy in the palliative care of MM in
developing countries. The definitive treatment still remains melphalan-prednisone (MP)
combination regimen as against the standard bortezomib-lenalidomide-dexamethasone
(RVD) triplet regimen used in developed countries. Stem cell transplantation is still a far
cry in the treatment of MM in the region due to its high cost and unavailability in the
region. About 7.6% of MM patients survive up to 5 years postdiagnosis in LICs. This is
below estimated 5 years postdiagnosis overall survival of 44.9% recorded by SEER cancer
statistics review of 1975–2007 in the USA. This chapter highlights management and some
of the diagnostic and therapeutic challenges encountered by people living with MM in
developing countries.
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1. Introduction
Multiple myeloma (MM), otherwise known as plasma cell myeloma, is a malignant plasma cell
disorder characterized by clonal proliferation of terminally differentiated B-lymphocytic cells
in the bone marrow. This leads to overproduction of aberrant immunoglobulins in the blood, a
condition known as paraproteinemia. It is one of the commonest hematological malignancies
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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of public health importance in low-income countries of Sub-Saharan Africa. It accounts for 10–
15% of all lymphohematopoietic cancers, 1% of all cancer diagnosis, and 0.9–2% of all cancer-
related deaths globally [1]. According to 2009 cancer statistics, the cumulative incidence of MM
in the United States is 20,580 cases with an estimated number of deaths of 10,580 and a case
fatality rate greater than 51% [2]. The prevalence of MM is in the increase in African continent
especially in the oil-rich Niger-Delta Nigeria where it accounts for about 8.2% of all hemato-
logical malignancies [3, 4]. The management of MM starts with a good history, which brings
into limelight the epidemiology, pathogenesis, and the clinical features of the disease. This is
followed by a series of investigations to make the diagnosis and to clinically stage the disease
before therapeutic interventions. The major challenges in the management of MM in develop-
ing countries are in the diagnosis and treatment. The duo are majorly responsible for the
complications, poor prognosis, and survival outcome of people living with MM in the region.
This chapter highlights the management of multiple myeloma and some of the challenges
encountered in the diagnosis and treatment of this disease in developing countries using
Nigerian experience as a prototype.
2. Etiopathogenesis of multiple myeloma and its significance in its
management
The etiology of multiple myeloma is unknown. However, previous studies have identified
factors implicated as “potentially etiologic multiple myeloma risk factors” [5, 6]. These factors
include increasing age (>65 years), male gender, black race, and positive family history (first-
degree family relatives) of multiple myeloma. Other causes include environmental agents such
as cumulative exposure to ionizing radiation and certain chemicals such as dioxin, herbicides,
and pesticides. There is a hypothesis that these specific pesticides are causatively linked to
myelomatogenesis through the hypothesized precursors of multiple myeloma such as essential
monoclonal gammopathy (MGUS) and solitary multiple myeloma (SMM) [7, 8].
Physiologically, a plasma cell is an immunologically activated B-cell that produces antibody. A
B-cell goes through series of rearrangement with the immunoglobulin gene to generate func-
tional antibody. It can enter into the circulation to interact directly with antigen to differentiate
into a short-lived plasma cell that lives for about 3 days. On the other hand, a myeloma cell is a
postgerminal center plasma cell that has undergone immunoglobulin gene recombination, class
switching, and somatic hypermutation, and homes to the bone marrow to become long-lived
plasma cell (i.e., can live for ≥30 days) [9]. Cytogenetically, MM is divided into two groups based
on karyotype gain or loss into hyperdiploid and non-hyperdiploid MM. The hyperdiploid MM,
which constitutes about 55–60% of MM primary tumor, is characterized by hyperdiploid karyo-
type with chromosome range of 48–78 and trisomies of odd number chromosomes, including
15, 9, 5, 19, 3, 11, 7, and 21 (ordered by decreasing frequency). The hyperdiploid variants are
typically the IgG kappa-typeswith bone involvements. The non-hyperdiploid karyotype accounts
for the remaining 40–45% of MM primary tumor, and it includes the hypodiploid or near-
tetraploid chromosome numbers (i.e., fewer than 48 or more than 74 chromosomes). Chromoso-
mal translocations affectmore commonly the non-hyperdiploid karyotypes. In terms of prognosis,
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hyperdiploid MM is better than non-hyperdiploid karyotype provided the former is not associ-
ated with deletion of chromosome 13 (RB1 gene and miRNA-15a/16-1 cluster dysregulation) and
17 (involving the TP53 locus) or amplification of chromosome 1q21 [9, 10]. The critical role of
pathogenesis of MM is to give insight into the biology of the disease. Also, the pathways of the
pathogenesis of the disease serve as potential sites for therapeutic interventions, especially the
target therapies, which can utilize them for their actions.
3. Requirements for standard diagnosis and staging of multiple myeloma
The diagnosis of multiple myeloma is based on a constellation of hematologic, immunologic,
histologic, and radiographic features. There are two methods of diagnosis of MM: the old and
new methods. In the old method, a minimum of two major criteria, or one major criterion plus
one minor criterion, or three minor criteria is used in making diagnosis of MM [11]. The major
criteria are plasmacytoma on tissue biopsy, bone marrow infiltration with greater than 30%
BMPCs, monoclonal globulin spike on serum electrophoresis, while the minor criteria include
bone marrow infiltration with 10–30% BMPCs, paraprotein less than the defined quantity for
major criteria, and lytic bone lesion. Table 1 shows the criteria for diagnosis of MM using the
old method. The newer method of diagnosis takes into cognizance of the popularly known
criteria which uses the end-organ damage as defined using both the classic as “CRAB” criteria
for hypercalcemia, renal failure, anemia, and bone lesions and additional criteria including
recurrent bacterial infections (> 2 in 12 months), amyloidosis, or symptomatic hyperviscocity.
In the newer method, initiation of therapy is an evidence of organ or tissue damage (end-organ
damage) [9]. Diagnosis is made by clonal BMPCs of not less than 10% of biopsy-proven bony
or extramedullary plasmacytoma or any evidence of myeloma-defining events. The myeloma-
defining events in this context include any evidence of end-organ damage or presence of any
one or more biomarkers of malignancy such as clonal BMPCs greater than 60%, serum-free
Major criteria:
I Plasmacytoma on tissue biopsy
II Bone marrow infiltration with >30% BMPCs
III Monoclonal globulin spike (paraprotein) on serum electrophoresis (IgG >35 g/L and IgA >20 g/L) or on concentrated
urine electrophoresis (>1 g/24 h or kappa or lambda light chain)
Minor criteria:
A = Bone marrow infiltration with 10–30% plasma cells
B = Paraprotein less than the level defined earlier
C = Lytic bone lesions
D = Normal IgM <0.5 g/L, IgA <1 g/L or IgG <6 g/L
Abbreviations: MM, multiple myeloma; BMPC, bone marrow plasma cell; IgG, immunoglobulin G; IgA, immunoglobulin
A; IgM, immunoglobulin M.
Table 1. Criteria for the diagnosis of MM (old method).
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1. Clonal BMPCs ≥10% of biopsy-proven bony or extramedullary plasmacytoma
Any one of the following myeloma-defining events:
• Evidence of end-organ damage that can be attributed to the underlying plasma cell proliferative disorder, specifi-
cally:
a. Hypercalcemia: serum calcium >0.025 mmol/L (>1 mg/dL) higher than the upper limit of normal
or >2.75 mmol/L (>11 mg/dL)
b. Renal insufficiency: creatinine clearance <40 mL per min or serum creatinine >177 μmol/L (>2 mg/mg/dL)
c. Anemia: hemoglobin value of 20 g/L below the lower limit of normal, or a hemoglobin value <100 g/L
d. Bone lesions: one or more osteolytic lesions on skeletal radiography, CT, or PET-CT
• Any one or more of the following biomarkers of malignancy:
a. Clonal bone marrow plasma cell percentage* ≥ 60%
b. Involved: uninvolved serum free light chain ratio ≥ 100
c. >1 focal lesions on MRI studies
*Clonal should be established by showing kappa/lambda-light-chain restriction on flow cytometry, immunohistochemis-
try, or immunofluorescence. BMPC percentage should preferably be estimated from a core biopsy specimen; in case of a
disparity between the aspirate and core biopsy, the highest value should be used.
Source: In Table 107-2 [9].
Table 2. Criteria for diagnosis of MM (newer method).
1. All of the following
Hemoglobin >10.5 g/dL
Serum calcium normal
X-ray showing normal bone structure or solitary bone plasmacytoma only
Low paraprotein levels
IgG < 50 g/L
IgA < 30 g/L
Urinary light chain <4 g/24 h
2. Fitting neither stage I or stage III
3. One or more of the following:
Hemoglobin <8.5 g/dL
Serum calcium >3 mmol/L




Urinary light chain >12 g/24 h
Subclassification
A. Serum creatinine <170 μmol/L
B. Serum creatinine ≥170 μmol/L
D-S, Durie-Salmon; IgG, immunoglobulin G; IgA, immunoglobulin A.
Table 3. D-S staging system.
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light chain ratio greater than 100, and or greater than one focal lesions on magnetic resonance
imagery studies. Table 2 shows the current criteria of diagnosis of MM.
The staging ofMM is another important step after diagnosis. The essence of staging is for decision-
making on therapeutic interventions and for prognostication of the disease. There are two clinical
staging systems for MM. They include the Durie-Salmon staging system and the international
staging system (ISS). The Durie-Salmon (D-S) clinical staging system has been in use for more than
30 years, but it has been remodified to a newer staging system useful for the assessment
of myeloma tumor mass [9, 12] The old D-S staging system has three stages (I, II, and III) and
two subclassifications (A and B). Here, the staging of MM is based on five parameters viz.: the
hemoglobin concentration, the serum calcium level, osteolytic bone lesions, serum, and urinary
immunoglobulin quantification. The subclassification A in the staging connotes “normal renal
status” (evidenced by normal serum creatinine level), while B connotes “abnormal renal state”
(evidenced by deranged serum creatinine level). This is shown in Table 3. The modified Salmon-
Durie assesses myeloma tumor mass using the old system to stage MM into high tumor mass
(stage III), low tumor mass (I), and intermediate tumor mass myelomas (II), which is shown in
Table 4. The ISS is based on two widely available parameters, serum beta-2 microglobulin and
albumin. This staging system recognizes three stages and can be useful for prognostication of
survival intervals of MM patients (Table 5) [13].
The standard assessment of MM requires a panel of investigations, which are carried out
periodically postdiagnosis for prognostication and monitoring of the disease response to
treatment. These investigations include complete blood count, blood chemistry, serum and
(I) High tumor mass (stage III) (>1.2  1012 myeloma cells/m2)*
One of the following abnormalities must be present
A. Hemoglobin <8.5 g/dL, hematocrit <25%
B. Serum calcium >12 mg/dL
C. Very high serum or urine myeloma protein production rates:
1. IgG peak >7 g/dL
2. IgA peak >5 g/dL
3. Urine light chains >12 g/24 h
D. More than three lytic bone lesions on bone survey (bone scan not acceptable)
(II) Low tumor mass (stage I) (<0.6  1012 myeloma cells/m2)*
All of the following must be present:
A. Hemoglobin >10.5 g/dl, or hematocrit >32%
B. Serum calcium normal
C. Low serum myeloma protein production rates:
1. IgG peak <5 g/dl
2. IgA peak <3 g/dl
3. Urine light chains <4 g/24 h
D. No bone lesions or osteoporosis
(III) Intermediate tumor mass (stage II) (0.6 to 1.2  1012 myeloma cells/m2)*
All patients who do not qualify for high or low tumor mass categories are considered to have intermediate tumor
mass
A. No renal failure (creatinine ≤2 mg/dl)
B. Renal failure (creatinine >2 mg/dl)
*Estimated number of neoplastic plasma cells.
Data adapted from Durie and Salmon [12]. A remodified D-S staging system.
Table 4. Assessment of myeloma tumor mass (Salmon-Durie).
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urine monoclonal protein assay, C-reactive protein, beta-2 microglobulin test, marrow study,
skeletal survey, echocardiogram, immunophenotyping, cytogenetic tests, etc. (Table 6).
4. Challenges in diagnosis of multiple myeloma
The prevalence of MM is on the increase in developing countries such as those found in Sub-
Saharan Africa [3, 14]. The oil-rich regions are worse hit probably due to a wide range of
environmental pollution, flaring of gases, water pollution, oil spillage, and lack of effective
environmental policies [6]. This is understandable based on the hypothesis that occupation
studies of chemical, petroleum, and radiation industry workers have provided inconsistent
evidence of causal association with MM [5]. Another potential etiologic factor that could be a
key player in the increasing prevalence is the median age of diagnosis. Studies in Nigeria,
Africa’s most populous black nation, have shown that the median age of diagnosis of multiple
Complete Blood Count and differential count; examination of blood film
Chemistry screen, including calcium, creatinine, lactate dehydrogenase, BNP, proBNP
β2-microglobulin; C-reactive protein
Serum protein electrophoresis, immunofixation, quantification of immunoglobulin, serum-free light chains
24-hour urine collection for protein electrophoresis, immunofixation, quantification of immunoglobulins, including light
chains
Marrow aspirate and trephine biopsy with metaphase cytogenetics, FISH, immunophenotyping; gene array, and plasma
labeling index (if available)
Bone survey and MRI; PET-CT
Echocardiogram with assessment of diastolic function and measurement of interventricular septal thickness; EKG (if
amyloidosis suspected)
BNP, brain natriuretic peptide, CT, computed tomography; EKG, electrocardiogram; FISH, fluorescence in situ hybridi-
zation, MRI, Magnetic resonance imaging; PET, positron emission tomography; proBNP, prohormone B-type natriuretic
peptide.
Source: In Table 107-4 [9].
Table 6. Assessment of myeloma.
Stage I β2M < 3.5
ALB ≥ 3.5




Stage III β2M > 5.5
ALB, serum albumin in g/dL; β2M,serum β2-microglobulin in mg/L.
Data from Greipp et al. [13].
Table 5. International staging system (ISS).
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myeloma is 59.9 years (45–78 years) [14–17]. This age is less than the 65 years median age of
diagnosis recorded by SEER cancer statistics review of 1975–2007 in the USA [18]. The impli-
cation of this early age of diagnosis is that more people may likely be diagnosed with MM by
the time they attend the age of 65, hence increasing the burden of the disease. The male to
female ratio of about 2:1 recorded by most of the studies shows a gender disparity of the
disease. However, the later may not have much role to play on the increased prevalence of MM
in developing countries.
There is a dearth of data on the diagnosis or prevalence of premalignant plasma cell disease in
low- and some middle-income countries. The two known hypothesized precursors of MM are
MGUS and smoldering MM. Based on retrospective data from Mayo clinic, MGUS is associ-
ated with 1% annual risk of progression to MM, while SMM has 10% annual risk of progres-
sion to MM. However, due to lack of resources for making diagnosis at this early stage, these
premalignant diagnoses are missed. This ultimately leaves the attending physicians with MM
patients who present at advanced stages of the disease.
The diagnosis of MM is made late, usually between Durie-Salmon stages II-A (intermediate
myeloma mass) and III-B (high myeloma mass) in developing countries [14–17]. The mean
duration from onset of symptoms to diagnosis in a study was 13.12 months (95% CI, 6.65–19.58)
[6, 17]. In some geographic regions, the onset of symptoms to diagnosis can last as long as 10 years
[17]. The lack of modern equipments for diagnosis and staging of the disease are the key players
in the late diagnosis of MM in most developing countries including Nigeria [14]. Most health
institutions in developing countries (especially the low-income) do not have the infrastructural
and medical capacities to handle comprehensive assessment investigations for MM patients. In a
recent study in Nigeria, it was found that only 72% of patients with a preliminary diagnosis of
MM could afford basic assessment tests required for confirmation and staging of the disease. Out
of this number, 43 and 55.7% could do immunoglobulin quantification and Bence Jones Protein
tests, respectively.
The commonest assessment tests done by the patients are hematocrit, erythrocyte sedimenta-
tion rate, skeletal x-ray, bone marrow aspiration, and trephine biopsy in centers where there
are hematologists [14–17]. About 56–60% of MM patients could afford serum electrolyte urea
and creatinine assessment tests required for staging the disease [Table 2], while less than 50%
of the patients could do serum protein, globulin, and albumin level estimation. The serum
albumin is one of the analytes essential for international prognostic staging of MM. The β2M,
serum immunofixation test, marrow aspirate and trephine biopsy with metaphase cytogenetic,
FISH, immunophenotyping, gene expression profiling (GEP), and plasma cell labeling index
(PCLI) are myeloma assessment tests, which are not readily available in developing countries
due to the cost and prevailing poverty in the countries. The implication of this is that most MM
diagnosed in these regions are cytogenetically unknown and are not internationally staged.
Hence, MM patients do not benefit from accurate risk stratification and prognostic assessments
as offered to their counterparts in developed countries [19].
These challenges in diagnoses and disease staging contribute to the poor survival outcome of
people living with MM in these regions. In a 10-year retrospective study of 26 MM patients in
Niger-delta region of Nigeria, only one (3.8%) of the patients could do a marrow metaphase
Management of Multiple Myeloma in Developing Countries
http://dx.doi.org/10.5772/intechopen.76500
213
cytogenetic (FISH) test and this happened to be a high risk category (t(4,14) immunoglobulin
A)multiple myeloma [3, 20]. In the study, only four subjects could afford immunofixation test,
which showed IgA:IgG-type myeloma ratio of 1:3 and this was in keeping with previous study
by Salawu and Durosimi [16].
5. Challenges due to skeletal related events (SREs) and other complications
MM poses a diagnostic dilemma for the orthopedic surgeons because of the frequent skeletal
manifestations.” It is usually misdiagnosed as an orthopedic disease when in the real sense it is a
hematologic disease with orthopedic complications. At advanced stage, it causes multiple lytic
bone lesions with severe osteoporosis and pathological fracture. A recent observational study in
Nigeria [14] found that about 84.6% of newly diagnosed multiple myeloma patients in Nigeria
presented with multiple bone lesions. Pathological fracture constitutes about 42.3% of SREs in
the MM patients in the region. It is surprising to note that 84.6% of all newly diagnosed MM are
referrals from orthopedic wards [3, 14]. The key players of the bone lesions in multiple myeloma
are cytokines namely IL-6 (Interleukin-6), TNF-alpha (tumor necrosis factor), vascular endothe-
lial growth factor (VEGF), platelet derived growth factor (PDGF), and insulin-like growth factor
(IGF). These cytokines, especially VEGF and PDGF, have angiogenic effect on the bone marrow
microenvironment and this effect favors the growth of myeloma cells in the bone. IL-6, an
important osteoclast-activating cytokine, plays an important role in the pathogenesis of osteopo-
rosis in MM [21]. Annibali et al. [22], in their pilot study, described the roles of these cytokines in
bone tissue destruction and the effect of zoledronic acid (a bisphosphonate) on their chemical
behaviors in MM patients. Other complications such as anemia, hemiplegia, nephropathy, and
constipation accounted for 61.5%, 35%, 23%, and 19% of newly diagnosed MM patients in same
study. Anemia in MM results from bone marrow invasion by abnormal plasma cells that secret
erythropoiesis-suppressive cytokines, and this anemia is usually anemia of chronic disorder [23].
6. Challenges of multiple myeloma treatment
The last step in the management of multiple myeloma is the therapeutic intervention. The
current standard treatment for MM is palliative care. This is a holistic treatment that offers
supportive, definitive, and psychosocial care for people living with MM [24]. There is a gross
inadequacy in the palliative care of MM in developing countries, hence the call to scale-up the
care of people living with MM. This is because of the life-threatening nature and the suffering
associated with the disease. A recent study has shown that inadequate palliative care accounts
significantly for the low survival interval of MM patients [3]. The overall survival interval of
MM patients in various studies in a developing country such as Nigeria showed a range of
3 months to 39.7 months [3, 15–17]. In one of the studies, it was found that only about 7.6% of
MM patients survive up to 5 years postdiagnosis. This was far below the estimated 5-year
period survival of 32 and 44.9% recorded by Ries et al. [25] and Altekruse et al. [26] in
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Surveillance, Epidemiology, and End Results (SEER) cancer statistics review of 1975–2002 and
1975–2007, respectively, in the USA. The implication is that many LMICs are more than 40
years backward in terms of management of MM compared to high-income countries such as
the USA. The two major challenges in the treatment of MM in developing countries are
anchored on the supportive and definitive treatment of MM.
6.1. Challenges in supportive treatment of MM
The standard supportive care for MM patients at advanced stage of the disease, which include
the use of analgesics, bisphosphonates (BPs), component blood therapy, antibiotics therapy,
renal dialysis viz-a-viz renal transplant, radiotherapy, orthopedic care, is grossly inadequate.
Chronic bone pain appears to be one of the commonest clinical features of MM, and analgesic
drug is the first supportive therapy offered to patients with the disease. However, in the
assessment and treatment of pain in MM patients in some low-income countries such as
Nigeria, the WHO analgesic ladder for cancer pain control is not usually adhered to, as only
few centers can access oral morphine and other opiate analgesics [27]. This leads to analgesic
abuse (self-medication), most of which are nephrotoxic, hence, worsening the prognosis of the
disease. A study showed that less than 40% of MM patients could afford BPs. BPs are useful in
preventing, reducing, and delaying MM SREs such as bone pain, osteoporosis, and other lytic
bone lesions. They can also help to control the growth of extramedullary tumors, hence the
need to scale-up their usage in MM [22, 28].
There is a gross inadequate access to radiation therapy in LICs including Nigeria. Studies have
shown that only about 3.8–20% (average 12%) of MM patients who need radiotherapy at one
point or the other of the disease could access it [3, 17]. The major reason is that the megavoltage
radiotherapy machine per population size is grossly inadequate (1-MV machine per 24 million
population as against the International Atomic Energy Agency (IAEA) requirement of 1-MV
machine per 250,000 population or per 350–400 new cancer patients in centers with excellent
cancer registry) [29].
About 60% of MM patients seen in LICs such as Nigeria present with severe grade of anemia
(hemoglobin <7 g/dL). The implication is that they will rely on blood transfusion therapy in
order to improve the quality of their life. Unfortunately, many of the LICs do not practice safe
blood transfusion. They depend majorly on commercial (paid) blood donation as against
voluntary non-remunerated blood donation (VNRBD), thereby predisposing the patients to
transfusion transmissible infectious diseases (TTIs) including HIV [30]. The facilities for com-
ponent blood therapy (i.e., apheresis machines) are not available in most health centers. For
instance, there was no documented beneficiary from component blood therapy in previous
studies in Nigeria. All severely anemic patients that require blood transfusion benefited from
either allogeneic whole blood transfusion (50%) or the use of erythroid growth factor such as
human recombinant erythropoietin (38%) [3, 14].
Infection is one of the major killers in MM in LICs, especially when immune paresis has set in.
About 11.1% of MM patients present with neutropenic sepsis in this region. Infection control is
by the use of antibiotic therapy/prophylaxis and colony forming unit-granulocyte-monocyte
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agents (CFU-GM) such as filgrastim or neupogen. However, the later is usually expensive and
only very few patients can afford it, hence worsening the survival outcome of the disease [3].
There is an increase in the incidence of nephropathy in MM in LICs. A range of 16–36% was
recorded in previous studies in Nigeria [3, 17, 31] as against 20% in the USA [32]. A striking
finding about the nephropathies in MM patients in LICs is their severity at presentation, which
qualifies most of them for renal dialysis (or renal transplant). However, this is an expensive
palliative intervention as only very few patients can comply with the courses of dialysis, which
may not be available in some centers.
In African continent, the major complications that bring MM patients to the hospital for the first
time are operable (surgical) complications. A recent study revealed that 56.7% of patients diag-
nosed with MM received different forms of surgery ranging from craniotomy (plasmacytoma of
the skull), partial cystectomy (solitary plasmacytoma of bladder), to internal fixation of orthope-
dic pins due to SREs complications arising frommyeloma cells. Surprisingly, these complications
have set in long before diagnoses were made. The presence of extramedullary plasmacytoma
indicates poor prognosis, and this is worsened further in the absence of involved field radiother-
apy (IFR) [33].
6.2. Challenges in definitive treatment of MM
The standard definitive interventions for people living with MM are antimyeloma chemotherapy
regimens and stem cell transplantation (autologous stem-cell transplantation (ASCT)). The
antimyeloma chemotherapeutic regimens have undergone series of transformation and evolution
over the years. The current antimyeloma therapeutic agents have changed the paradigm in the
management of the disease. These agents have the best effect in improving the quality of life and
overall survival intervals of MM patients. They have positively changed the course of the disease
especially in high-income countries where they are relatively more available. This has been due in
large part to a better understanding of the biology of the disease and the development of several
highly effective therapies. They include proteasome inhibitors [PI] (bortezomib, carfilzomib,
ixazomib, marizomib, and oprozomib), immunomodulatory [IMiD] agents (thalidomide, lenalid-
omide, and pomalidomide), monoclonal antibody therapies (elotuzumab, daratumumab, and
siltuximab), Bcl inhibitor (navitoclax), FGFR3 inhibitor (dovitinib), and histone deacetylase
(HDAC) inhibitors (panobinostat, romidepsin, vorinostat, and rocilinostat). These agents include
those that target the myeloma itself, some that target the bone marrow microenvironment, and
those that target both [34].Unfortunately, these agents are not readily available in low- and some
middle-income countries (LMICs) including Nigeria. The huge disparity in income, health-care
infrastructure, and access to novel drugs in LMICs hinders the delivery of optimum care to every
patient with MM in the region [35] due to limitation in purchasing power.
Theremaybeno “standard therapy” forMMtreatment, based on themanynovel therapies,which
have emerged for the treatment of the disease. The treatment approaches that are often referred to
as standard are usually those with strong evidence of clinical efficacy. Although a recent clinical
trial has shown that a combination of PI and IMiDwill make for a standard regimenwhen added
with dexamethasone [36], the current opinion is in favor of individualized treatment options,
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which is based not only on cytogenetic risk classification, but also on host factors, disease stage,
and a variety of other prognostic factors.
According to the National Comprehensive Cancer Network (NCCN) guidelines, the consensus
standard of care in newly diagnosedMMwho have no intention for ASCT is RVD (lenalidomide,
bortezomib, and dexamethasone) [36]. This is because RVD has improved median overall sur-
vival (OS) compared to conventional RD (75 months versus 64 months; HR 0.709; two-sided
p = 0.025), improved overall response rate [ORR] (82 versus 72%), and improved progressive-free
survival (PFS) (43 months versus 30 months, HR 0.712; one-sided p = 0.0018) [37, 38].
This consensus standard of treatment of MM is yet to be achieved in many developing
countries. Unlike in developed countries where treatment is beginning to be customized
based on mapping of patient’s genome, most low-income countries are yet to offer their
patients such opportunities. In Nigeria, the major antimyeloma chemotherapy drug is the
old conventional alkylating agent known as melphalan (M), which is usually combined with
a steroid (i.e., prednisolone, P) as a double or triple-only combination regimen. MP is still the
most accessible commonly used regimen for treating MM patients because of the cost and
availability, long after it has been phased out for treating MM patients in developed countries.
About 84% of newly diagnosed MM patients in some LICs still depend on MP doublet combi-
nation regimen [3].This is contrary to the standard RVD triplet regimen accepted worldwide as
the current treatment of choice for MM. About 28% of MM patients from the group of patients
already on MP could afford a “partial-standard” triplet regimen made up of either one PI (i.e.,
bortezomib-melphalan-prednisolone VMP (7.7%)) or one IMiD agent (i.e., thalidomide-
melphalan-prednisolone TMP (19.7%). “Partial” in this context connotes combination of a target
(novel) therapy with old conventional regimen (i.e., MP in this case). However, a recent study in
Nigeria has shown that up to 16.7% of MM patients use bortezomib-thalidomide-dexametha-
sone (BTD) as their first-line regimen [39]. Although RVD has a better median overall survival
(OS), progressive free survival (PFS) and overall response rate (ORR) compared to BTD, this is a
move toward the right direction as the latter regimen is close to the standard regimen (RVD) in
terms of the benefits derived from a PI and IMiD combination regimens [36]. But, again, this is a
bad news for many developing countries as less than 20% of MM patients in the region could
access close-to-standard (partial) antimyeloma regimen [40]. The remaining 16% constitute the
MM patients who are either on unclassified (i.e., neither known old conventional nor new novel
therapy) antimyeloma regimens (such as vincristine adriamycin dexamethasone VAD, CVP, and
CVAP) or not on any cytotoxic chemotherapy [3].
Stem cell transplantation (i.e., ASCT) is not a common option of treatment of MM in most
developing countries. The only patient (3.8%) who benefited from this intervention from
a previous study was outside Nigeria and the patient died two years posttransplantation.
There is paucity of data regarding stem cell transplantation in most LICs especially those from
Sub-Saharan African region. For instance, no center offers ASCT in Nigeria presently.
Although few successful attempts on allogeneic stem-cell transplantation have been made in
a center in Southern Nigeria (on sickle cell disease), but it has not been sustainable due to
technological inequalities, brain drain of health workers, lack of funding, and political-will
from the government. The public health system does not guarantee health insurance coverage
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for oncology treatment and stem-cell transplantation. Transplant-eligible patients who require
stem-cell transplantation usually pay out from their pockets, and this could add to another
burden to the patients [41–43]. However, in high-income countries, the reverse is the case and
the survival outcome is usually better.
7. Other challenges
7.1. National Cancer (MM) Registry
There is no standard National cancer (MM) registry or Surveillance Epidemiology End-Result
(SEER) cancer statistics review center in most developing countries including Nigeria. This has
hindered getting accurate statistics of the disease in most developing countries.
7.2. National Guideline for management of MM
There are no standard guidelines for the treatment of MM in many developing countries
including Nigeria. This is responsible for the disparities in some of the outcomes. A lot of
confounding issues have arisen as a result of disharmony in the management of the disease in
many developing countries. There is a need to control all confounding issues that may arise as
a result of heterogeneous management of the MM in developing countries. Each country is
expected to design its own consensus guidelines that will best serve the patients putting
international best practices in mind.
7.3. Psychosocial input
One of the components of a good palliative care of people living with terminal diseases such as
MM is the psychosocial care. In developed countries, the social workers and the spiritualists
have their roles to play in order to improve the quality of life of the patients. For instance, some
patients who have financial challenges in procuring their treatment may not access social
workers either because they are not there or they might be there but they are not functioning.
This may create more health burden or even cause death of the patients in some cases.
8. Conclusion and recommendations
Late diagnosis and inadequate palliative care are the hallmarks of poor prognosis and overall
survival outcome of MM in developing countries [3]. There is a need to educate the physicians,
especially orthopedic surgeons, renal physicians, and gastroenterologists to exercise higher
index of suspicion, as they are usually the first to see such patients [44].
The government, stakeholders in health institutions, and donor agencies who are passionate for
MM have a role to play in its management toward improving the quality of life of people living
with the disease. This is achievable by improved funding of MM research and treatment in
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developing countries. The public health system should as a matter of urgency provide health
insurance coverage for the management of MM patients especially in LICs such as Nigeria where
the over 62% of population lives on extreme poverty of less than two dollars per day [41].
There is also a need to build special centers designated for the treatment of MM where all
relevant modern health-care facilities/equipments for diagnosis, risk assessments, and treat-
ment of MM should be available, while taking into cognizance international best practices for
the management of the disease.
Adequate access to radiation therapy is a crucial component of modern multidisciplinary
cancer care including MM. There must be a strict adherence to the IAEA recommendation of
one megavoltage machine per 400 new cancer patients in areas with excellent cancer registry
or one per 250,000 population size in areas without excellent cancer registry. The implication is
that in countries like Nigeria where there are barely five functioning radiotherapy machine, the
number has to be scaled up between 260 and 840 megavoltage units taking into cognizance a
population size of 210 million people (based on 2006 population census and average annual
growth rate of 3.1%) [29].
Supportive care of people living with MM must take into cognizance psychosocial health of
the individuals and their families. This is the only way forward in ensuring a holistic care and
improved quality of life of these patients. Every component of palliative workforce including
the social workers must be involved in realizing this goal.
There is a need to scale-up definitive treatment of MM in developing countries using stem-
cell transplantation. Autologous non-cryopreserved stem-cell transplantation avoids the cost
of establishing and maintaining a cryopreservation facility, and this can be feasible in trans-
plant centers in economic-constrained regions [45, 46]. Studies have shown that high-dose
melphalan with autologous stem-cell support improves the survival rate for patients with
myeloma. Also, when they are carefully selected for treatment with ASCT, they can be
managed with a brief initial hospitalization and outpatient follow-up, with low morbidity
and mortality [47–50].
Also, efforts should be intensified to set up excellent cancer (MM) registries in developing
countries so as to improve on the statistics and epidemiology of MM and other cancer diseases.
Each country is expected to formulate its own consensus guidelines that will best serve the
patients using international best practices.
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